Health Check: Biotechs obey the Three Commandments of life sciences
Anatara has taken a different tack post-trial results, while Chimeric is raising funds and Imugene proposes a share consolidation
Heramed falls victim to US healthcare funding cuts
D-Day looms for Mayne Pharma holders – or will there be a twist?
Biotechs are heeding the Three Commandments of Life Sciences, as evidenced by ASX announcements over the last few days.
Why have only three emerged from the Mount?
Inspired by Donald Trump's famed negotiating skills and the supermarkets' shrinkflation practices, we managed to whittle them down from ten – and got adultery removed for good measure.
Anatara cuts the pineapple in other ways
Commandment One: when a clinical trial faileth, do not throweth in the towel prematurely.
In the case of Anatara Lifesciences (ASX:ANR), the company dipped out with a phase II trial testing its drug candidate – Garp – on irritable bowel syndrome (IBS) patients.
Garp, as in Gastrointestinal ReProgramming, contains a form of bromelain, an enzyme found in pineapple stems of all things.
Enlisting 78 volunteers, the study failed to meet the primary endpoint of a meaningful improvement in IBS symptoms, compared to placebo.
This was despite a 40% 'sustained and consistent' improvement, as measured by the IBS symptom scoring system.
The gist is that while there was an 'apparent trend of pain and distension relief', the more subjective measures did not show a clear pattern of improvement and this affected the overall score.
For example, questions included "how dissatisfied are you with your bowel functioning the past 10 days?"
The answers 'appeared to confound the result, presumably because the underlying disease is still present with a level of symptomatology'.
Anatara is continuing its anti-obesity pre-clinical studies, which are expected to take about six months to complete.
The other lesson here is that in devising primary endpoints, one should be-eth bloody careful to picketh the right ones.
Chimeric seizes the day
Commandment Two: Don't wasteth a successful trial result: go-eth to the well.
True to that lore, Chimeric Therapeutics (ASX:CHM) on Friday requested a trading halt 'pending an announcement in relation to a capital raising'.
The shares are frozen until tomorrow, or possibly today if the news come through.
On Thursday Chimeric shares soared 60%, or two-thirds of the cents after the company said two out of three evaluable patients in its phase IIb trial had achieved a complete response.
A complete response means remission or – in layman's terms – a cure.
The third patient had 'achieved stable disease, whereby the cancer is neither increasing nor decreasing in extent or severity'.
The study tested Chimeric's natural killer (NK) cells, agents in the blood stream with heightened cancer busting powers.
Chimeric's candidate, CHM-0201 was administered alongside standard-of-care chemotherapy patients to the for acute myeloid leukemia.
The three patients are the first to be targeted of 20 subjects, with 12 enrolled as of December.
The first patient was dosed in June last year.
The three patients were ineligible for transplantation and had not been previously treated.
Honey – we shrunk the share base
Commandment Three: when one's share price plummeteth, one should seeketh to consolidate one's shares.
Imugene (ASX:IMU) proposes a share consolidation to reduce its circa 7.46 billion shares on issue by a factor of 34, subject to investor approval at an EGM.
Imugene shares have fallen more than 70% over the last two years – and lost close to 10% this morning.
In theory, the shares would be worth 68 cents a share post-consolidation.
Apart from the 'vibe' of a company no longer being in 'penny dreadful' territory, share consolidations don't change anything fundamentally.
Heramed loses US hospital partner
HeraMED (ASX:HMD) has fallen victim to Trumpian public healthcare funding cuts, with hospital partner Broward Health ceasing use of the company's digital foetal monitoring tool Heracare.
Heramed says Broward believed that Heracare worked quite well, including reducing pre-term births significantly.
But the First, Second and Third Commandment of US healthcare is that economic imperatives come before clinical ones.
As a Medicaid 'safety net' hospital, Broward took up Heracare courtesy of a state grant. As of April 1 this year, federal allotments to the states to fund such services have been reduced by US$8 billion annually.
Heramed has appointed a US healthcare commercialisation firm, Aspire Health Innovations, to further its US growth.
The company also is in commercial discussions with potential partners 'in other markets with stable healthcare policy environments.'
Vitura pots another one
Medical cannabis intermediary Vitura Health (ASX:VIT) has added another chain of clinics to its range of outlets, albeit indirectly.
Vitura's 50% joint venture Flora has acquired the digital platform Heyday Medical, 'one of Australia's most respected medicinal cannabis clinics'.
Established in 2020, the chain claims to have services more than more than 5000 patients.
The deal involves Flora paying $350,000 in cash, plus a 15% stake in Flora post-deal, the value of which has not been quantified.
Vitura owns the Canview marketplace, Doctors on Demand telehealth business, CDA Clinics (medical cannabis telehealth) and a the clinic chain Candor Medical.
Last November Flora acquired the Releaf Group, which operates telehealth and physical clinics.
Mayne and Island shares have a rest
Mayne Pharma (ASX:MYX) shares are in trading halt until Wednesday, pending news of a 'material announcement' pertaining to US dermatological group Cosette's $7.40 a share cash takeover offer.
Last Thursday, Mayne issued an independent report opining the offer was 'fair and reasonable', with an assessed value of $6.61 to $7.50 per share.
Barring any surprise, Mayne holders will meet on June 18 to approve the scheme of arrangement.
Meanwhile, Island Pharmaceuticals (ASX:ILA) shares are on trading halt pending a capital raising.
The developer of both a treatment and prophylactic for dengue fever, Island had cash of $4.8 million as of the end of March.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sydney Morning Herald
an hour ago
- Sydney Morning Herald
The airline facing a double-whammy after Trump's bunker-busting
You've probably never heard of Mike Murphy – but he is the guy who was choking on his smashed avocado toast at about 9am on Sunday when US President Donald Trump dropped his massive ordnance penetrators on three Iran nuclear installations. Murphy runs the Australian arm of Bain, the majority owner of airline Virgin, which is set to list on the Australian market on Tuesday as the highest profile ASX entrant in years. Timing is everything for investing, and for Bain, the timing of the Virgin listing looks atrocious. Those investors who bought in pre-listing and who were looking to sell out immediately – for what are referred to as stag profits – may need to rethink. Airlines, in particular, are highly sensitive to any geopolitical conflict and they are even more vulnerable to those in oil-producing territories. Loading First, this is because the oil prices surges, and for airlines, fuel is one of the major costs. Second, international airline flights can be disrupted, redirected or in some cases, those that fly over affected areas will temporarily abandon services. Already, British Airways and Singapore Airlines have suspended a number of flights to the Gulf, affecting routes to key hubs such as Dubai, Doha and Bahrain, citing safety concerns and evolving airspace restrictions.
Herald Sun
an hour ago
- Herald Sun
Virgin Airlines domestic and international flight sale has fares from $49
Don't miss out on the headlines from Lifestyle. Followed categories will be added to My News. Fancy a sneaky getaway? Like us, you're probably too busy planning your next holiday to keep an eye on who is debuting on or returning to the Australian Stock Exchange. But today is a good one to be across this as Virgin is celebrating its re-appearance on the ASX with a stonker of a sale called Bell To Boarding. How long does the sale last? It closes on 11.59 AEST Friday June 27, 2025. When can I travel? Between July 22, 2025 and March 26, 2026. What are the lowest fares? One way domestic Economy Lite tickets start at $49. This, for example, will get you to Ballina from Sydney or vice versa. Looking international? Return flights from Melbourne to Queenstown, for example, start at $455. Are Economy X seats on sale? Yes. For travellers looking to upgrade their experience, Economy X is also on sale until June 27, 2025 on selected routes with extra legroom starting from $27 per person per sector on select domestic routes (such as Adelaide to Canberra or vice versa) and starting from $39 per person per sector on international routes (such as Brisbane to Fiji). What international destinations are included? Queenstown, Denpasar, Nadi and Vanuatu are all on offer. What does the sign mean on airline website sale sites? This indicates that the one way ticketed fare is available in both directions. Big savings on Virgin right now. What are some of the domestic flights in this sale? The following flights are all one-way economy lite fares valid in both directions: Melbourne-Launceston from $59, Sydney-Gold Coast from $65, Melbourne-Gold Coast from $89, Melbourne-Uluru from $99. As with all flight bookings be sure to read the terms and conditions attached to your ticket. What are some of the international flights in this sale? The following flights are all return economy lite fares valid in both directions: Sydney-Queenstown from $489, Brisbane-Vanuatu from $489 and Sydney-Nadi (Fiji) from $595. As with all flight bookings be sure to read the terms and conditions attached to your ticket. Can you accrue frequent flyer points on these flights? Yes. All Virgin Australia sale fares include the ability for Velocity Frequent Flyer members to earn Velocity Points and Status Credits. For the full list of flights on sale click here Originally published as Virgin drops massive four day sale with fares from $49
News.com.au
2 hours ago
- News.com.au
$3.2 million prize home up for sale a month after huge sweepstakes win
The winner of a prize home in Queensland valued at more than $3 million is selling the home just a month after they got it. A resident of Urunga NSW was announced to have won 66 Templeton Wy, Doonan, on May 14, in a prize draw run by the charity yourtown. With commitments outside of Queensland, the vendor decided to sell the four-bedroom, three-bathroom home at an upcoming auction. The house is nestled deep in the Noosa Hinterland accessed through a long driveway inside a private cul-de-sac. The home will be sold fully furnished, including furniture and appliances valued at around $200,000. At the Prize Draw, yourtown valued the home at around $3.2 million. Now, the home is being sold by agents Kess Prior & Ruth Venning of Hinternoosa Real Estate. 'It's north facing, it's flooded with natural light, it's absolutely beautiful,' Ms Prior said. 'It's like stepping into a new life.' The modern Queenslander was owned for nearly 10 years before being sold for the sweepstakes, offering an elevated position over the nearby bush. The house itself has a covered deck around every side, along with ducted airconditioning and a gas fireplace. Outside, garden lighting leads into a large pool, along with a cubby house near the back of the property. The home is less than 20 minutes from both Eumundi and Noosa Heads, and less than half an hour away from the coast's airport. 'Templeton Way is one of the best streets in the Hinterland,' Ms Prior said. 'I think it's gonna be a cracking auction.' The auction will take place from midday on July 18, with the first open home at 1pm on Wednesday, June 25.
